Skip to main content
2022 Guide to Patient Support Services

TerSera Therapeutics

2022 Oncology Guide to Patient Support Services

TerSera SupportSource

TerSera Therapeutics offers the TerSera SupportSource program to help patients while taking a TerSera oncology medicine (Table).

TerSera SupportSource

This program helps remove the financial and access barriers that patients sometimes encounter through their drug-specific programs, including the Varubi Co-Pay Card, Xermelo Co-pay Program, Zoladex Co-Pay Card, and the TerSera Therapeutics Patient Assistance Program.

Varubi and Zoladex Co-Pay Cards

Eligible patients who are commercially insured may pay as little as $0 per prescription with an annual cap of $2000. Patients may be eligible if they:

  • Have commercial insurance coverage
  • Reside in the United States
  • Do not participate in any federal, state, or other government health insurance program, such as Medicare, Medicaid, or Veterans Affairs.

Click here to enroll your patient in the Varubi Co-Pay Card; click here to enroll in the Zoladex Co-Pay Card.

Xermelo Co-pay Program

This program reduces or eliminates out-of-pocket costs for patients taking Xermelo. Patients with commercial insurance may pay as little as $0 with a maximum of $10,000/year. To learn more or to enroll your patient in the Xermelo TerSera SupportSource program, click here or call 844-937-6356.

TerSera Therapeutics Patient Assistance Program

This program provides free TerSera medicine for up to 1 year to qualifying patients. Medicine can either be sent to your office or to your patient’s home. Patients may be eligible if they:

  • Are a US citizen or have a Green Card or Work Visa
  • Meet certain household income limits (call 855-686-8725 for details)
  • Do not have prescription drug coverage for their TerSera medicine, with the exception of Xermelo.

See Table for drug-specific enrollment sites.

TABLE TerSera Oncology/Supportive Care Drugs

Patient support programs

Varubi (rolapitant)
Prevention of delayed nausea and vomiting in adults associated with emetogenic cancer chemotherapy, including highly emetogenic chemotherapy, in combination with other antiemetic agents
Patient support programs

Xermelo (telotristat ethyl)
Treatment, in combination with a somatostatin analog, of carcinoid syndrome diarrhea that is inadequately controlled by somatostatin analog therapy
Patient support programs

Zoladex (goserelin implant)
Management of localized prostate cancer, in combination with flutamide; palliative treatment of advanced prostate cancer; palliative treatment of advanced breast cancer in pre- and perimenopausal women
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"